Health Blueprint

Back to Longevity News

News summary

The nerve switch Sironax wants to keep switched off

Source: Longevity Technology • Published: 06 Nov 2026, 16:15

Summarized by Masters of Longevity from Longevity Technology.

SIR2501 posted safety and early activity signals in ALS and CIPN studies.

The nerve switch Sironax wants to keep switched off
Key Takeaways
  • SIR2501 showed favorable safety and early activity signals.
  • Global Phase 1b/2 trials in ALS and CIPN are running.
  • Key numeric details and patient counts were not reported.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.